Copyright
©The Author(s) 2024.
World J Hepatol. Sep 27, 2024; 16(9): 1199-1205
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1199
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1199
Figure 1 Hepatitis B virus life cycle and novel drug targets.
NTCP: Sodium taurocholate co-transporting polypeptide; rcDNA: Relaxed circular DNA; cccDNA: Covalently closed circular DNA; CRISPR: Clustered regularly interspaced short palindromic repeats; Cas9: CRISPR-associated protein 9; mRNA: Messenger RNA; pgRNA: Pregenomic RNA; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B envelope antigen; HBcAg: Hepatitis B core antigen; HBcrAg: Hepatitis B core related antigen; TALEN: Transcription Activator-like Effector Nucleases; ZFP: Zinc-Finger Proteins; CpAM: Capsid assembly modulators; siRNA: Short interfering RNA; ASO: Antisense oligonucleotides; NAP: Nucleic acid polymer; HBx: Hepatitis B X protein; HBs: Hepatitis B S protein; HDAc: Histone deacetylase; FXR: Farnesoid X receptor; PegIFN: Pegylated interferon; NA: Nucleotide analogue.
- Citation: Ray G. Functional cure of chronic hepatitis B-hope or hype? World J Hepatol 2024; 16(9): 1199-1205
- URL: https://www.wjgnet.com/1948-5182/full/v16/i9/1199.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i9.1199